Akanda

Akanda FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Akanda (AKAN) as of Oct 26, 2026 is 17.44 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 148.40 % — a change of -88.25% (lower).

FCF Conversion

17.44 %

YoY

-88.25%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Akanda is 2025 17.44 % . FCF Conversion Rate (FCF/EBITDA) of Akanda was 2024 148.40 % . It decreases by -88.25% lower compared to the previous year.

The Akanda FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
70.34 USD
Jan 1, 2020
77.88 USD
Jan 1, 2021
87.73 USD
Jan 1, 2022
101.05 USD
Jan 1, 2023
4.65 USD
Jan 1, 2024
148.40 USD
Jan 1, 2025
17.44 USD
The Akanda FCF Conversion history
YEARFCF ConversionYoY
17.44 %-88.25%
148.40 %+3,088.67%
4.65 %-95.39%
101.05 %+15.18%
87.73 %+12.65%
77.88 %+10.72%
70.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

FCF Conversion Rate (FCF/EBITDA) of Akanda is 17.44 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Akanda changed from 148.40 % to 17.44 %, representing a -88.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Akanda since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Akanda with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Akanda

All Key Metrics — Akanda